A Myriad of Pathways to NASH

被引:34
作者
Larrain, Soledad [1 ]
Rinella, Mary E. [1 ]
机构
[1] Northwestern Univ, Div Gastroenterol & Hepatol, Dept Med, Feinberg Sch Med, Chicago, IL 60611 USA
关键词
Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis; NASH; Drug; Nutrition; Endocrine; Metabolism; NONALCOHOLIC FATTY LIVER; INTESTINAL BACTERIAL OVERGROWTH; MITOCHONDRIAL BETA-OXIDATION; INFLAMMATORY-BOWEL-DISEASE; HEPATIC CB1 RECEPTORS; CHAIN ACYL-COENZYME; PLASMA-FREE CHOLINE; GROWTH-HORMONE; PARENTERAL-NUTRITION; INSULIN-RESISTANCE;
D O I
10.1016/j.cld.2012.05.009
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Nonalcoholic steatohepatitis (NASH) is defined histopathologically by the presence of macrovesicular steatosis, cellular ballooning, and inflammation. NASH represents a complex multifactorial disease that typically occurs within the context of the metabolic syndrome. NASH lacks homogeneity, and other forms of NASH can present atypically. Less than 50% of patients with NASH respond to pharmacologic treatment, which speaks to this heterogeneity. The authors discuss drugs, disease entities, and nutritional states that can cause or exacerbate underlying NASH indirectly through worsening insulin resistance or directly by interfering with lipid metabolism, promoting oxidative injury, or activating inflammatory pathways.
引用
收藏
页码:525 / +
页数:26
相关论文
共 50 条
[31]   The role of REV-ERB in NASH [J].
Griffett, Kristine ;
Hayes, Matthew E. ;
Boeckman, Michael P. ;
Burris, Thomas P. .
ACTA PHARMACOLOGICA SINICA, 2022, 43 (05) :1133-1140
[32]   Labeled breath tests in patients with NASH: Octanoate oxidation relates best to measures of glucose metabolism [J].
Mucinski, Justine M. ;
Perry, Alisha M. ;
Fordham, Talyia M. ;
Diaz-Arias, Alberto ;
Ibdah, Jamal A. ;
Rector, R. Scott ;
Parks, Elizabeth J. .
FRONTIERS IN PHYSIOLOGY, 2023, 14
[33]   Trimethylamine N-oxide levels are associated with NASH in obese subjects with type 2 diabetes [J].
Leon-Mimila, P. ;
Villamil-Ramirez, H. ;
Li, X. S. ;
Shih, D. M. ;
Hui, S. T. ;
Ocampo-Medina, E. ;
Lopez-Contreras, B. ;
Moran-Ramos, S. ;
Olivares-Arevalo, M. ;
Grandini-Rosales, P. ;
Macias-Kauffer, L. ;
Gonzalez-Gonzalez, I ;
Hernandez-Pando, R. ;
Gomez-Perez, F. ;
Campos-Perez, F. ;
Aguilar-Salinas, C. ;
Larrieta-Carrasco, E. ;
Villarreal-Molina, T. ;
Wang, Z. ;
Lusis, A. J. ;
Hazen, S. L. ;
Huertas-Vazquez, A. ;
Canizales-Quinteros, S. .
DIABETES & METABOLISM, 2021, 47 (02)
[34]   Efficacy of docosahexaenoic acid-choline-vitamin E in paediatric NASH: a randomized controlled clinical trial [J].
Zoehrer, Evelyn ;
Alisi, Anna ;
Jahnel, Joerg ;
Mosca, Antonella ;
Della Corte, Claudia ;
Crudele, Annalisa ;
Fauler, Guenter ;
Nobili, Valerio .
APPLIED PHYSIOLOGY NUTRITION AND METABOLISM, 2017, 42 (09) :948-954
[35]   Immune and Inflammatory Pathways in Non-Alcoholic Steatohepatitis (NASH). An update [J].
Coste, Sorina Cezara ;
Popovici, Ionela ;
Stefan, Andreea Maria ;
Breaban, Iulia ;
Taut, Adela Sitar ;
Sarlea, Simina Tarmure ;
Cozma, Angela ;
Sampelean, Dorel ;
Orasan, Olga Hilda ;
Negrean, Vasile ;
Procopciuc, Lucia Maria .
JOURNAL OF MIND AND MEDICAL SCIENCES, 2019, 6 (01) :52-57
[36]   Mitochondrial Dysfunction in the Transition from NASH to HCC [J].
Leveille, Melissa ;
Estall, Jennifer L. .
METABOLITES, 2019, 9 (10)
[37]   Incretin as a Novel Treatment Strategy for NAFLD/NASH [J].
Takeda, Yasuo ;
Ikeda, Ryuji ;
Kondo, Tomoko .
YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, 2016, 136 (04) :573-577
[38]   Managing the Burden of Non-NASH NAFLD [J].
Christopher J. Danford ;
Jorge E. Sanchez ;
Kathleen E. Corey .
Current Hepatology Reports, 2017, 16 (4) :326-334
[39]   Genetics and epigenetics of NAFLD and NASH: Clinical impact [J].
Eslam, Mohammed ;
Valenti, Luca ;
Romeo, Stefano .
JOURNAL OF HEPATOLOGY, 2018, 68 (02) :268-279
[40]   Hypertension, diabetes, atherosclerosis and NASH: Cause or consequence? [J].
Lonardo, Amedeo ;
Nascimbeni, Fabio ;
Mantovani, Alessandro ;
Targher, Giovanni .
JOURNAL OF HEPATOLOGY, 2018, 68 (02) :335-352